Discounted Cash Flow
Rigel Pharmaceuticals Inc.
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2016 | $20.4m | $-69.2m | $-76.7m | -339.6% | — |
| 2017 | $4.5m (-78.0%) | $-78.0m (-12.7%) | $-77.7m (-1.3%) | -1739.3% (-412.2%) | — |
| 2018 | $44.5m (892.6%) | $-70.5m (9.6%) | $-59.9m (22.9%) | -158.3% (90.9%) | — |
| 2019 | $59.3m (33.2%) | $-66.9m (5.1%) | $-43.0m (28.3%) | -112.8% (28.7%) | $-0.40 |
| 2020 | $108.6m (83.2%) | $-29.7m (55.5%) | $-53.4m (-24.4%) | -27.4% (75.7%) | $-0.18 (55.0%) |
| 2021 | $149.2m (37.4%) | $-17.9m (39.8%) | $5.3m (109.8%) | -12.0% (56.2%) | $-0.11 (38.9%) |
| 2022 | $120.2m (-19.4%) | $-58.6m (-227.0%) | $-74.2m (-1513.2%) | -48.7% (-305.8%) | $-0.34 (-209.1%) |
| 2023 | $116.9m (-2.8%) | $-25.1m (57.2%) | $-5.7m (92.3%) | -21.5% (55.9%) | $-0.14 (58.8%) |
| 2024 | $179.3m (53.4%) | $17.5m (169.7%) | $31.4m (647.4%) | 9.8% (145.4%) | $0.99 (807.1%) |
| 2025 | $294.3m (64.1%) | $367.0m (1999.1%) | $75.7m (140.7%) | 124.7% (1178.8%) | $20.40 (1960.6%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.